Third Rock-backed au­toim­mune biotech turns off the lights

A Third Rock Ven­tures biotech cre­at­ed to make new med­i­cines for au­toim­mune and in­flam­ma­to­ry dis­eases has shut­tered, End­points News has learned.

Rheos Med­i­cines changed its reg­is­tered of­fice ad­dress and reg­is­tered agent last month to that of a Foxbor­ough, MA ac­count­ing firm that spe­cial­izes in bank­rupt­cies, per Jan­u­ary doc­u­ments. A Third Rock spokesper­son con­firmed to End­points that Rheos wound down “late last year.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER